Rocket Pharmaceuticals’ (RCKT) “Market Perform” Rating Reaffirmed at Leerink Partners
Leerink Partners reiterated their market perform rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat reports. Leerink Partners currently has a $8.00 price target on the biotechnology company’s stock, down from their prior price target of $37.00. Several other research analysts have also […]
Leerink Partners reiterated their market perform rating on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat reports. Leerink Partners currently has a $8.00 price target on the biotechnology company’s stock, down from their prior price target of $37.00. Several other research analysts have also […]
